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Abstract: Importance A promising treatment to prevent onset and improve outcomes in patients at
ultrahigh risk for psychosis is dietary supplementation with long-chain ￿-3 polyunsaturated fatty acids
(PUFAs). Objective To determine whether treatment with ￿-3 PUFAs in combination with a high-
quality psychosocial intervention (cognitive behavioral case management [CBCM]) is more effective than
placebo plus CBCM. Design, Setting, and Participants NEURAPRO, a double-blind, placebo-controlled,
randomized clinical trial, was conducted fromMarch 1, 2010, to September 30, 2014, in 10 specialized early
psychosis treatment services in Australia, Asia, and Europe. The primary analysis used the intention-
to-treat approach. Interventions A daily dose of 1.4 g of ￿-3 PUFAs or placebo (paraffin oil), plus
20 or fewer sessions of CBCM over the 6-month study period. Main Outcomes and Measures The
primary outcome was transition to psychosis status at 6 months. The secondary outcomes were general
levels of psychopathology and functioning, as assessed by the Brief Psychiatric Rating Scale (BPRS)
(range, 24-168), Scale for the Assessment of Negative Symptoms (SANS) (range, 0-125), Montgomery-
Åsberg Depression Rating Scale (MADRS) (range, 0-60), Young Mania Rating Scale (YMRS) (range,
0-44), Social and Occupational Functioning Assessment Scale (SOFAS) (range, 0-100), and the Global
Functioning: Social and Role scale (range, 0-10). For SOFAS and Global Functioning: Social and Role
scale, higher scores were better; for other measures, lower scores were better. Results In this study of 304
adults at ultrahigh risk for psychotic disorders, 153 (50.3%) received ￿-3 PUFAs and 151 (49.7%) received
placebo. In all, 139 (45.7%) were male; mean (SD) age was 19.1 (4.6) years. The Kaplan-Meier-estimated
6-month transition rates were 5.1% (95% CI, 1.3%-8.7%) in the control group and 6.7% (95% CI, 2.3%-
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group and 11.5% (95% CI, 5.8%-16.9%) in the ￿-3 PUFA group. No significant difference was observed
between the transition rates of both groups (hazard ratio, 1.1; 95% CI, 0.55-2.23; P = .76, stratified
log-rank test). Conclusions and Relevance This trial clearly failed to replicate the findings of the original
single-center trial. The most likely explanation is that ￿-3 PUFAs lack efficacy under these conditions.
However, the lower-than-expected transition rate may have prevented a test of the main hypothesis.
Given the substantial symptomatic and functional improvement in both groups, the other treatments
received (ie, CBCM and antidepressants) likely produced a ceiling effect beyond which ￿-3 PUFAs, even
if effective, could not be shown to confer additional benefits. Nevertheless, the main conclusion is that
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IMPORTANCE A promising treatment to prevent onset and improve outcomes in patients at
ultrahigh risk for psychosis is dietary supplementation with long-chain ω-3 polyunsaturated
fatty acids (PUFAs).
OBJECTIVE To determine whether treatment with ω-3 PUFAs in combination with a
high-quality psychosocial intervention (cognitive behavioral case management [CBCM]) is
more effective than placebo plus CBCM.
DESIGN, SETTING, AND PARTICIPANTS NEURAPRO, a double-blind, placebo-controlled,
randomized clinical trial, was conducted fromMarch 1, 2010, to September 30, 2014, in 10
specialized early psychosis treatment services in Australia, Asia, and Europe. The primary
analysis used the intention-to-treat approach.
INTERVENTIONS A daily dose of 1.4 g of ω-3 PUFAs or placebo (paraffin oil), plus 20 or fewer
sessions of CBCM over the 6-month study period.
MAIN OUTCOMES ANDMEASURES The primary outcomewas transition to psychosis status at
6months. The secondary outcomes were general levels of psychopathology and functioning,
as assessed by the Brief Psychiatric Rating Scale (BPRS) (range, 24-168), Scale for the
Assessment of Negative Symptoms (SANS) (range, 0-125), Montgomery-Åsberg Depression
Rating Scale (MADRS) (range, 0-60), YoungMania Rating Scale (YMRS) (range, 0-44), Social
and Occupational Functioning Assessment Scale (SOFAS) (range, 0-100), and the Global
Functioning: Social and Role scale (range, 0-10). For SOFAS and Global Functioning: Social and
Role scale, higher scores were better; for other measures, lower scores were better.
RESULTS In this studyof 304adults at ultrahigh risk for psychotic disorders, 153 (50.3%) received
ω-3PUFAs and 151 (49.7%) receivedplacebo. In all, 139 (45.7%)weremale;mean (SD) agewas
19.1 (4.6) years. TheKaplan-Meier–estimated6-month transition rateswere 5.1% (95%CI, 1.3%-
8.7%) in the control group and6.7% (95%CI, 2.3%-10.8%) in theω-3 PUFA group. At 12months,
the rateswere 11.2% (95%CI, 5.5%-16.7%) in the control group and 11.5% (95%CI, 5.8%-16.9%)
in theω-3 PUFA group. No significant differencewas observed between the transition rates of
both groups (hazard ratio, 1.1; 95%CI, 0.55-2.23; P = .76, stratified log-rank test).
CONCLUSIONS AND RELEVANCE This trial clearly failed to replicate the findings of the original
single-center trial. Themost likely explanation is that ω-3 PUFAs lack efficacy under these
conditions. However, the lower-than-expected transition rate may have prevented a test of
themain hypothesis. Given the substantial symptomatic and functional improvement in both
groups, the other treatments received (ie, CBCM and antidepressants) likely produced a
ceiling effect beyond which ω-3 PUFAs, even if effective, could not be shown to confer
additional benefits. Nevertheless, the main conclusion is that ω-3 PUFAs are not effective
under conditions where good quality, evidence-based psychosocial treatment is available.
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P sychotic illnesses typically emerge from initially subtleand relativelynonspecific symptoms, building througha prodromal period of subthreshold positive symp-
toms to cross a somewhat arbitrary threshold that enables a
first episode of psychosis to be diagnosed.1 The operational
definition of the ultrahigh risk (UHR) mental state,2,3 which
prospectively identifies people at incipient risk of progres-
sion to full-threshold psychosis, has catalyzed an intense re-
search effort as well as significant reforms to clinical care.4,5
The validation of the UHR criteria has enabled the study of a
rangeof treatment strategies to relievedistress, improve func-
tioning, and reduce the risk for progression to a psychotic
illness.2,3,6-14
Eleven trials assessing psychosocial or pharmacologic in-
terventions, aloneor in combination, havebeen carriedout in
UHRcohorts. A recentmeta-analysis has shown that these in-
terventions are effective, resulting in an overall risk reduc-
tion of 54% at 12 months with a number needed to treat of 8
(range, 4-13).15 All treatments appeared to reduce the riskdur-
ing the first 6 to 12 months. In line with the clinical staging
model of illness,16-20 during the earliest stage of illness, safer
interventions, suchas long-chainω-3polyunsaturated fattyac-
ids (PUFAs) and cognitivebehavioral therapy (CBT), shouldbe
regardedas thepreferredoptions for first-line treatment. Cog-
nitive behavioral therapy, awell-established and safe psycho-
social intervention adapted for this stage of illness, has been
found to be effective in many, although not all, of the pub-
lished trials.21-26However, themost striking result todatewas
the finding that ω-3 PUFAswere superior to placebo in reduc-
ing the risk for transition to psychosis and psychiatric mor-
bidity in general, not only during the period of treatment, but
also fora subsequentlyprolonged time (median,6.7years).27,28
Safe and beneficial to health inmanyways, ω-3 PUFAs repre-
sent a simple and relatively inexpensive potential treatment
strategy. The initial ω-3 PUFAs study27 was therefore clearly
worthy of attempted replication.
Methods
Study Design and Setting
NEURAPROwas adouble-blind, placebo-controlled, random-
ized clinical trial of ω-3 PUFA therapy given for 6months, fol-
lowedby an additional 6-month follow-upperiod, in 304par-
ticipantswhoreceivedeitherω-3PUFAstogetherwithcognitive
behavioral casemanagement (CBCM) or placebo with CBCM.
The total study period was 12 months fromMarch 1, 2010, to
September 30, 2014. Assessments were made at baseline, 6,
and 12 months after entry. In addition, assessments of psy-
chopathology were conducted monthly during the first 6
months and also at month 9. The 6- and 12-month results are
reportedherein. The studywasperformed in accordancewith
the Declaration of Helsinki29 and is consistent with Interna-
tional Council for Harmonisation of Good Clinical Practice.30
TheNational Health andMedical Research Council of Austra-
lia National Statement on Human Research was also adhered
to, appropriateethical approvalwasobtainedbyeachsite (Mel-
bourne, Australia: Melbourne Health Research Ethics Com-
mittee; Sydney,Australia: SydneySouthWestAreaHealthSer-
vice Ethics Review Committee; Basel, Switzerland: Ethics
Commission for Basel; Zurich, Switzerland: Cantonal Ethics
CommissionZurich; Jena,Germany:UniversityClinic JenaEth-
ics Commission; Copenhagen, Denmark: Capital Region Re-
search Ethics Committee; Hong Kong: Institutional Review
Boardof theUniversityofHongKong/HospitalAuthorityHong
KongWest Cluster; Vienna, Austria: Medical University of Vi-
enna Ethics Commission; Singapore: National Healthcare
Group Domain Specific Review Board; and Amsterdam, the
Netherlands: Academic Medical Centre Medical Ethics Com-
mittee), and any local regulatory requirements were met be-
fore the trial commenced. Written informed consent was ob-
tained; for those younger than 17 years, parental or guardian
consent was sought. Participants received financial compen-
sation. Complete details on the study methodology are re-
ported by Markulev et al,31 and the trial protocol is available
in Supplement 1.
Help-seeking individuals attending trial centers were eli-
gible to participate if they were aged 13 to 40 years and met
the UHR criteria. In a variation to the previous UHR interven-
tion studies, all participants either hada low level of function-
ing (Social and Occupational Functioning Assessment Scale
[SOFAS] scores <50) sustained for at least a year or had expe-
rienced a significant decrease in their functioning (≥30% re-
duction in their SOFAS score) over the past year.32 Exclusion
criteria includedapreviouspsychotic episodeof 7daysor lon-
ger, current symptomsdue toacute intoxication, organicbrain
disease, serious developmental disorder, abnormal coagula-
tion profile or thyroid function, physical illness with a psy-
chotropic effect, current treatmentwithmoodstabilizers, past
neuroleptic exposure to a total lifetime haloperidol equiva-
lent dose of more than 50 mg, IQ of less than 70, dangerous
behavior, aggression or suicidality, pregnancy, or current
supplementation with ω-3 PUFA.31
Randomization
Participantswere randomized at study entry to either theω-3
PUFA plus CBCM group, or the placebo plus CBCM group via
anonline electronic datamanagement system (Figure 1). Ran-
domizationwas stratified by site and total score on theMont-
gomery-Åsberg DepressionRating Scale (MADRS) (total score
Key Points
Question Are ω-3 polyunsaturated fatty acids (ω-3 PUFAs)
effective in reducing transition to psychosis in young people at
ultrahigh risk for psychotic disorders on a background of
psychosocial and other care?
Findings In a multicenter, randomized clinical trial of 304
patients, no evidence of efficacy for ω-3 PUFAs was found.
Outcomes were equally positive in both the ω-3 PUFA and placebo
groups, with low transition rates and overall symptomatic
functional improvement.
Meaning Use of ω-3 PUFAs is not effective under conditions in
which evidence-based and good-quality psychosocial treatment
are available.
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range, 0-60, with the lowest score indicating the best level)33
since both depression and antidepressants may affect UHR
symptomsand illnessprogression.34-37All participants andcli-
nicians involved in delivering interventions, assessing out-
comes, and data entry were blind to group assignment. The
trial statistician (H.P.Y.) was unblinded at the analysis stage.
Study Interventions
Participants receivedeitherω-3PUFAsorplacebotogetherwith
clinical care with up to 20 sessions of CBCM for the 6-month
interventionphase, afterwhichadministrationofboth theω-3
PUFAs andplacebowere ceased, althoughpatients could con-
tinue to access CBCM on the basis of need throughout this
6-month follow-up.31 A total of 125 participants (41.1%) con-
tinued to receiveCBCMafter the6-month follow-upvisit,with
a mean (SD) of 4.1 (3.7) (range, 1-16) sessions attended.
For the first 12 months of the study, therapy with selec-
tive serotonin reuptake inhibitors was permitted for treat-
ment of moderate to severe major depression (MADRS score
≥21 for at least 2 consecutive weeks), and benzodiazepine
therapy was permitted for anxiety. The use of antipsychotics
or mood stabilizers was not permitted at any time during the
trial unless a participant was withdrawn from the study be-
fore 12months and these treatments were deemed necessary
according to clinical guidelines.
The studymedication comprised a daily dose of 4 gelatin
capsules throughout the 6-month treatment period. Partici-
pants were dispensed bottles of capsules, with each capsule
containing either (1) 0.65 to0.75 g of concentratedmarine fish
oil (active intervention: 840mg of eicosapentaenoic acid and
560mgof docosahexaenoic acid or approximately 1.4 g of ω-3
PUFAs per day) or (2) 0.65 to 0.75 g of paraffin oil (placebo in-
tervention).Thisdosewassimilar tothat inthepreviousstudy.27
OutcomeMeasures
The primary outcome was transition to psychosis status at 6
months,with transitiondefinedonthebasisofoperationalized
criteriaandassessedwiththeComprehensiveAssessmentof the
At-RiskMental State.32Diagnoses (bothpsychotic andnonpsy-
chotic)weredeterminedwith theStructuredClinical Interview
forDSM-IV-TRAxis I Disorders,38 and the secondarymeasures
included the Brief Psychiatric Rating Scale (BPRS) (total score
range, 24-168),39 Scale for the Assessment of Negative Symp-
toms (SANS) (total score range, 0-125),40MADRS,33 YoungMa-
niaRatingScale (YMRS) (total score range,0-44),41 SOFAS (total
score range, 0-100),42 and the Global Functioning: Social and
Role scales (total score range, 0-10).43 For SOFAS and Global
Functioning:Social andRole scale, thehigher thescore thebet-
ter; for the othermeasures, the lower the score the better.
Adherence to the studymedicationwas assessedmonthly
for eachparticipant basedon capsule count. Themeanadher-
ence rating over the 6-month intervention period was then
computed and categorized as either adherent (≤25% of cap-
sules returned) or nonadherent (>25% of capsules returned).
Adverse events and serious adverse events were monitored
throughout the study and were assessed at each visit during
the intervention phase and classified into categories for fur-
ther analysis.
Statistical Analysis
The studywas powered to detect a 13%difference in the tran-
sition ratesbetween the2 treatmentgroups,with the6-month
Figure 1. CONSORTDiagram of Participant Distribution
977 Individuals screened
673 Excluded304 Randomized
114 Completed
17 Transitioned
153 Randomized to ω-3 PUFAs
153 Received ω-3 PUFAs
as randomized
Lost to follow-up
14 Withdrew
24 Unable to contact
1 Pregnant
111 Completed
15 Transitioned
151 Randomized to placebo
151 Received placebo
as randomized
418 Ineligible
39 Past psychotic episode
4 Organic brain disease
4 Abnormal coagulation/
thyroid
2 Physical illness with
psychotropic effect  
32 Treatment with mood
stabilizer, use of ketamine
49 Past neuroleptic exposure
10 Developmental disorder
13 IQ <70, developmental
delay, or intellectual
disability
4 Aggression
13 Suicidality
2 Pregnancy
4 Attenuated symptoms by
acute intoxication
25 Regular ω-3
supplementation
112 Psychotic on referral
105 Other
155 Refused
100 Unable to provide consent
Lost to follow-up
18 Withdrew
22 Unable to contact
Randomization was stratified by site
andMontgomery-Åsberg Depression
Rating Scale score (<21 and21;
higher scores indicate worse
symptoms). Adherence rates were
43.1% for the ω-3 polyunsaturated
fatty acids (ω-3 PUFAs) group and
41.1% for the placebo group.
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transition rate in the placebo group assumed to be 15%.31 The
primaryanalysisusedthe intention-to-treatapproachandcom-
pared the difference in transition rates between the treat-
ment groups using survival analysis with the stratified log-
rank test andCox regressionanalysiswith recruitment site and
baseline MADRS score (<21 and ≥21) used as stratifying fac-
tors. General linearmodeling and linearmixed-effectsmodel
analysiswereused tocompare thesecondaryoutcomes (symp-
toms and functioning) for the 2 groups. Further analysis to
compare the treatments was conducted by taking adherence
into account for both the primary and secondary outcomes.
Risk class analysis was also undertaken using demo-
graphic characteristics (age, sex, race, years of education, and
durationofuntreated symptoms) and symptomand function-
ingmeasures (BPRS, SANS,MADRS,YMRS, SOFAS, andGlobal
Functioning: Social andRole) as potential risk factors to iden-
tify a subgroup of patientswhomight be at a relatively higher
riskof transition.The2 treatmentswere thencomparedwithin
this subgroup in terms of the primary and secondary out-
comes using the above-mentioned statistical methods. Sig-
nificancewas set atP = .05.Dataanalysiswas conductedusing
SPSS, version 22I (BM Corp) and S-PLUS, version 6.1 (Insight-
ful Corp).
Results
Study Sample
The study cohort consisted of 304 individuals, with 153 per-
sons randomly assigned to ω-3 PUFA treatment (50.3%) and
151 to placebo (49.7%). The baseline characteristics of both
groups were similar (eTables 1 and 2 in Supplement 2). Four-
teen of the 153 participants (9.2%) from the ω-3 PUFA group
and 18 of 151 individuals (11.9%) from the placebo group dis-
continued the intervention prematurely (ie, <6 months).
Twenty-four (15.7%)participants fromtheω-3PUFAgroupwere
unable to be contacted and 1 person (0.6%) becamepregnant,
and 22 (14.6%) participants from the placebo group were un-
able to be contacted. Thus, a total of 79 participants (26.0%)
were lost to follow-up (Figure 1). The mean (SD) duration of
untreated illnesswas 891.1 (969.1) days (median, 467 days) in
the ω-3 group and 897.6 (115.6) days (median, 431.5 days) in
the placebo group.
Efficacy
Primary OutcomeMeasure
The stratified log-rank test indicated no significant differ-
encebetweenω-3PUFAsandplacebo intransitionrate (P = .76).
The Kaplan-Meier–estimated 6-month transition rates were
5.1% (95% CI, 1.3%-8.7%) in the control group and 6.7% (95%
CI, 2.3%-10.8%) in theω-3PUFAgroup.At 12months, the tran-
sition rates were 11.2% (95% CI, 5.5%-16.7%) in the control
group and 11.5% (95% CI, 5.8%-16.9%) in the ω-3 PUFA group
(Figure 2). Cox regression analysis, again stratified for recruit-
ment site and baseline MADRS score, also showed no signifi-
cant difference between the 2 groups (hazard ratio [HR], 1.1;
95% CI, 0.55-2.23; P = .76).
Secondary OutcomeMeasures
General linear model analysis, with an a priori significance
threshold of P < .05 and no adjustment for multiple testing,
was used to compare treatments on changes in symptom and
functioning measures between baseline and the 6- and 12-
month follow-up visits. Twomeasures showed an almost sig-
nificant improvementatmonth6: theMADRS(P = .09)and the
SOFAS(P = .07),andastatisticallysignificant improvementwas
seenon theGlobalFunctioning: Social andRole scale (P = .02).
However, thedirectionof thesechangeswas in favorof thepla-
cebogroup.No statistically significantdifferencewas seenbe-
tween the groups in any of themeasures at month 12 (Table).
Linearmixed-effectsmodelingwasusedtocompare the2treat-
ments in the rate of improvement over time for each of the
symptomand functioningmeasures.Although therewasa sig-
nificant improvement over time for eachmeasure, the rate of
improvement did not significantly differ between ω-3 PUFAs
and placebo on any of the measures (Table).
Adverse Events
Adverse events were assessed at baseline and monthly dur-
ing the intervention phase, and then at the 6- and 12-month
follow-up visits. A number of adverse events were recorded
in both groups. The incidence rates ranged from less than 1%
(increased bleeding) to about 30% (gastrointestinal prob-
lems). No adverse events were regarded as serious adverse
events related to study medication (eTable 3 in Supplement
2).
Adherence and ConcomitantMedication
There were 66 adherent participants (43.1%) in the ω-3 PUFA
group and 62 in the placebo group (41.1%). However, a total
of 83participantshadmissingdata for the capsule counts (ω-3
PUFA, 35; placebo, 48), 9ofwhom(10.8%) transitioned topsy-
chosis. To avoid losing participants from the analysis, these
83 individuals were assumed to be nonadherent. Figure 3
shows the survival curves comparing the 2 groups for the ad-
herent and nonadherent participants. As expected, the tran-
sition rate was lower in the adherent participants; however,
Figure 2. Survival Curves of the Rate of Transition to Psychosis in the ω-3
Polyunsaturated Fatty Acid (ω-3 PUFA) and Placebo Groups
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Table. General LinearModel Analysis Comparing the Placebo and ω-3 PUFAGroupsa
Characteristicb
General Linear Model Analysis Linear Mixed-Effects Model Analysis
Month 6 Minus Baseline Month 12 Minus Baseline
P Valued
Overall Estimated
Rate of Change (SE) P ValueeMean (SD) P Valuec Mean (SD) P Valuec
Brief Psychiatric Rating Scale
Total
Placebo −7.4 (8.5)
.36
−7.8 (8.4)
.10 .48 −0.02 (0.0015) <.001
ω-3 PUFAs −7.3 (8.5) −7.8 (9.3)
Psychotic subscale
Placebo −2.4 (3.2)
.85
−2.5 (3.3)
.66 .91 −0.006 (0.0005) <.001
ω-3 PUFAs −2.3 (2.5) −2.3 (3.1)
Scale for the Assessment of Negative Symptoms
Total
Placebo −6.5 (11.7)
.14
−6.2 (11.7)
.89 .82 −0.018 (0.0020) <.001
ω-3 PUFAs −5.9 (9.6) −7.5 (11.7)
Affective flattening or blunting
Placebo −1.8 (4.6)
.24
−1.4 (4.8)
.89 .49 −0.005 (0.0008) <.001
ω-3 PUFAs −1.9 (4.0) −2.2 (4.8)
Alogia
Placebo −0.8 (2.6)
.14
−0.6 (2.4)
.60 .62 −0.002 (0.0004) <.001
ω-3 PUFAs −0.8 (2.4) −1.1 (2.5)
Avolition-apathy
Placebo −1.4 (3.0)
.45
−1.5 (3.4)
.72 .60 −0.004 (0.0005) <.001
ω-3 PUFAs −1.3 (2.8) −1.7 (2.9)
Anhedonia–asociality
Placebo −2.1 (4.0)
.40
−2.3 (4.3)
.80 .59 −0.005 (0.0007) <.001
ω-3 PUFAs −1.7 (3.5) −2.0 (4.3)
Attention
Placebo −0.4 (1.4)
.22
−0.3 (1.5)
.20 .92 −0.001 (0.0003) <.001
ω-3 PUFAs −0.3 (1.8) −0.7 (1.8)
Young Mania Rating Scale
Total
Placebo −1.1 (3.0)
.24
−0.9 (2.6)
.61 .70 −0.002 (0.0005) <.001
ω-3 PUFAs −0.9 (3.1) −0.8 (3.1)
Montgomery-Åsberg Depression Rating Scale
Total
Placebo −9.3 (8.4)
.09
−9.0 (−9.6)
.72 .79 −0.020 (0.0016) <.001
ω-3 PUFAs −7.9 (8.7) −9.6 (−9.4)
Social and Occupational Functioning Assessment Scale
Placebo 12.6 (14.9)
.07
14.3 (16.8)
.95 .36 0.036 (0.0030) <.001
ω-3 PUFAs 8.9 (16.5) 14.7 (19.1)
Global Functioning
Social
Placebo 0.6 (1.4)
.45
0.7 (1.6)
.47 .41 0.002 (0.0003) <.001
ω-3 PUFAs 0.5 (1.2) 0.5 (1.4)
Role
Placebo 0.9 (1.6)
.02
1.0 (2.0)
.78 .63 0.002 (0.003) <.001
ω-3 PUFAs 0.5 (1.7) 0.9 (1.7)
Abbreviation: ω-3 PUFAs, ω-3 polyunsaturated fatty acids.
a Change between baseline and follow-up (months 6 and 12) and linear
mixed-model analysis comparing the 2 treatments for rate of change over
time.
b For the Brief Psychiatric Rating Scale, score range is 24 to 168; lowest score
indicates the best level.39 For the Scale for the Assessment of Negative
Symptoms, score range is 0 to 125; lowest score indicates the best level.40 For
the YoungMania Rating Scale, score range is 0-44; lowest score indicates the
best level.41 For theMontgomery-Åsberg Depression Rating Scale, score range
is 0-60; lowest score indicates the best level).33 For the Social and
Occupational Functioning Assessment Scale, score range is 0-100; higher
scores are better.42 For the Global Functioning: Social and Role scales, score
range is 0-10; higher scores are better.43
c Placebo vs ω-3 PUFA groups for change at month 6 to 12 vs baseline.
d Placebo vs ω-3 groups for improvement from baseline to month 12.
e Overall estimated rate of change.
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stratified log-rank tests comparing the 2 treatment groups
showed that therewasno significantdifferencebetween them
regardless of adherence status (adherent, P = .38; nonadher-
ent, P = .95) (Figure 3).
Thesymptomand functioningmeasureswere further ana-
lyzedby takingadherence intoaccount, againusinggeneral lin-
earmodeling and a linearmixed-effectsmodel. Again, no sig-
nificant differencebetween the2 treatment groupswas found
(P > .14 for all measures), regardless of adherence status.
Themean (SD)numberofCBCMsessionsattendedwas 11.2
(6.4) for the ω-3 PUFA group and 10.3 (6.0) for the placebo
group. The overall median number of CBCM sessions at-
tended was 8 (range, 1-35). Again, stratified log-rank tests
showed that there was no significant difference between the
treatment groups in terms of transition rate for those with a
number of CBCM sessions equal to or below the median
(P = .31), aswell as for those above themedian (P = .50). Con-
comitant medication use after randomization included anti-
depressants in 98 (64.1%) of those in the ω-3 PUFA group and
91 (60.3%) of those in the placebo group (P = .57) and anxio-
lytics in 32 (20.9%) of the participants in the ω-3 PUFA group
and 44 (29.1%) of those in the placebo group (P = .13).
Risk Class Analysis
Risk class analysiswasundertaken in an effort to identify par-
ticipants at the highest risk of transition to assess the effec-
tiveness of ω-3 PUFA in this subgroup. Demographic charac-
teristics and symptom and functioning measures were used
aspotential risk factors and their significanceon transition rate
was determined using Cox regression analysis in the placebo
group to remove any potential intervention effect. The only
measures found to be significant were BPRS total score (HR,
1.07;95%CI, 1.01-1.13;P = .03)andMADRStotal score (HR, 1.09;
95% CI, 1.02-1.18; P = .009). Because these 2 measures were
highly correlated (Pearsoncorrelation,0.67), theMADRSscore
waschosenas thestratifying factor for this analysis since ithad
a lowerPvalue, hadnomissing values, andwas 1 of the strati-
fying variables for the randomization. A cutoff score of 14 for
theMADRSwas found to correspond to themost significantP
value (P = .001). This scorewas consideredvalid becausepar-
ticipants in the placebo group who had a MADRS total score
lower than 14 had an estimated 1-year transition rate of 0%,
whereas those with a score of 14 or higher had an estimated
1-year transition rate of 16.5%. However, when the transition
ratesof the2 treatmentgroupswerecomparedwithin thehigh-
risk (ie, those with a MADRS score ≥14) cohort, no significant
difference was found (Figure 4).
Discussion
To our knowledge, this is the first randomized, placebo-
controlled,multicenter clinical trial to test theefficacyof long-
chainω-3PUFAs inpreventing transition topsychosis inyoung
Figure 3. Survival Curves for the Rate of Transition in the ω-3 Polyunsaturated Fatty Acid (ω-3 PUFA) and Placebo Groups Based on Adherence Status
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A, A total of 176 participants were nonadherent. B, A total of 128 participants were adherent.
Figure 4. Survival Curves for the Rate of Transition in Ultrahigh-Risk
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Ultrahigh risk was considered a Baseline Montgomery-Åsberg Depression
Rating Scale score of 14 or higher.
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people at UHR for psychosis. Although ω-3 PUFAs were well
tolerated, they did not demonstrate an advantage over pla-
cebo in the prevention of psychosis at 6- or 12-month fol-
low-up evaluations. Secondary outcomemeasures of psychi-
atric symptoms and functioning tended to favor the placebo
group. This outcome is difficult to explain other than as a
chance finding. The results represent a clear failure to repli-
cate the earlier single-center trial.27,28
Although theobvious andmost likely explanation for this
nonreplication is thatω-3 PUFA supplementation is not effec-
tive for preventing the onset of psychosis, it remains at least
possible that other explanations may have been responsible.
The 12-month transition rate of 10.5% was lower than ex-
pected andbelow the rate of 16.1%seen in theprevious single-
center trial.27 There are 2 possible explanations for this lower
transition rate. First, themanualized CBCM intervention and
the high level of antidepressant treatment received by both
treatment groups in the present study may have been suffi-
cientlyeffective tohaveproducedaceilingeffectbeyondwhich
there was no scope for ω-3 PUFAs to confer additional ben-
efit. If so, themain hypothesismay not have been testable. In
support of this possibility is the fact that the placebo group in
the original trial failed to show the level of symptomatic and
functional improvement seen in the present study.44 Second,
the sample may have been insufficiently enriched for risk of
transition. At first glance the low transition rate might be re-
garded as having reduced the power of the study to detect an
effect; however, since there was no indication of efficacy of
theω-3PUFAs,morepower througha larger sample sizewould
not have helped. It remains possible that ω-3 PUFAs may be
beneficial in the absence of other treatments or possibly in a
subsample of cases. Longer-term follow-up, subgroup analy-
sis, and additional studies may clarify these issues.
Lower transition rates have been observed over the past
decade and several possible explanations have been
considered.45-48 These explanations include reduced dura-
tion of symptoms and lesser initial severity and enrichment,
yet we found no evidence for this in the present study. Many
trials have shown that CBT is effective in delaying and reduc-
ing transition,15 and in contrast to the original study,27 all pa-
tients in the present study received substantial levels of high-
quality CBT-based intervention. In addition, the high
proportionof participantswho receivedantidepressantmedi-
cation (62% vs 10% in the original study) may also have con-
tributed to the low overall transition rate and better dimen-
sional outcomes. Previous studies have suggested aneffect of
antidepressant medication in decreasing that transition rate
inUHRsamples.34-37 In thepresentstudy,antidepressantmedi-
cation was prescribed for participants who were more symp-
tomatic anddepressed, andwho thereforewere at higher risk
of transition to psychosis, thus potentially having a selec-
tively greater effect on reducing the overall transition rate.
Strengths of the study include the randomized, placebo-
controlled design, the use of standardized inclusion and exit
criteria, interrater reliability testing, the monitoring of treat-
ment adherence, and the confirmation at 12-month fol-
low-up by means of standardized interview and case review
that all peoplewhomet the exit criteria hadmade transitions
to genuine psychotic disorders.
Limitations
A limitationof this study is that theuse of nonstudyω-3 PUFA
supplements cannot be excluded and the test agentmay thus
be present in both the treatment and control groups.49 Non-
study ω-3 PUFA intake may have decreased the difference in
ω-3 PUFA status between the groups, since both awareness of
thepotential health benefits and availability ofω-3 PUFAshas
increased over the past decade.
Therapeutic effects of ω-3 PUFAs may be present in sub-
groups characterized by certain biological or phenotypic
markers28 that can be considered as moderators of clinical
response.50Thesesupplementsarespecificallyeffective insub-
groups of depression characterized by high levels of
inflammation.51 Subgroup analyses using baseline mem-
brane fatty acid levels and inflammatorymarkers areplanned.
We are also investigating whether biological measures of ω-3
PUFA intake that accurately define adherence to studymedi-
cation, as well as nonstudy intake, such as changes in eryth-
rocytemembrane fatty acid levels,will provide a clearer view
ofwhetherω-3PUFAs showedanybenefit in subgroupsof this
cohort.
Conclusions
This trialhas failed to replicate the findingsofaprevioussingle-
center study.27Othermulticenter trials, ongoinganalysisof the
data from the present study, and future research will help to
ultimatelydeterminewhetherω-3PUFAshave a role in the re-
duction of risk and early treatment of psychotic disorder.
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